CORONA Remedies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: CORONA BSE: 544644

₹2034.20

Oct. 5, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #42 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	427,010	143.5	13.7%	7.6%	—	72	8	30
Divi's Laboratories Limited	244,125	83.0	15.3%	57.8%	0.33%	70	4	51
Torrent Pharmaceuticals Limited	161,506	77.7	12.2%	35.3%	0.80%	56	0	31
Zydus Lifesciences Limited	113,616	32.6	17.3%	14.5%	0.09%	74	24	84
Cipla Limited	107,888	35.1	11.2%	-11.7%	0.97%	73	29	62
Laurus Labs Limited	106,505	122.0	17.1%	128.4%	—	78	24	53
Mankind Pharma Limited	102,382	46.9	11.7%	0.9%	—	68	12	86
Dr. Reddy's Laboratories Limited	100,411	150.9	10.9%	-3.7%	—	62	33	71
CORONA Remedies Limited (this stock)	12,441	62.6	—	—	0.49%	80	0	23

Quarterly Financials

Download CSV

Standalone Consolidated

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	422	80	60	₹
March 31, 2026	353	55	45	₹
Dec. 31, 2025	342	55	41	₹
Sept. 30, 2025	361	70	52	₹

The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,403	240	185

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	229	-256	25	174	55

Balance Sheet (consolidated)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,205	747	686	143	0	348	361	2	291	125